Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 25.85% is in line with its 5-year average of 26.85%, around the middle of its 5-year range (8.36%–34.70%).
29.99% above its 12-month average of 19.89%.
Reported quarterly gross margin; no daily interpolation. Q3 FY2026 (2026-07-31): 11.38%.
GROSS MARGIN
25.85%
GROSS MARGIN AVG TTM
19.89%
GROSS MARGIN AVG 3Y
26.67%
GROSS MARGIN AVG 5Y
26.85%
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+29.99%
CURRENT VS 3Y AVG
-3.07%
CURRENT VS 5Y AVG
-3.73%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
42.92%
median of 565 covered companies
CURRENT VS SECTOR MEDIAN
-39.77%
vs the sector median at left
Market Cap
$241.56M
Gross Margin
-24677.94%
TTM Avg
-13289.35%
3Y Avg
-6830.59%
5Y Avg
-4553.73%
Market Cap
$239.06M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$243.66M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$243.81M
Gross Margin
N/A
TTM Avg
31.32%
3Y Avg
30.59%
5Y Avg
32.68%
Market Cap
$236.90M
Gross Margin
79.48%
TTM Avg
71.93%
3Y Avg
74.52%
5Y Avg
72.98%
Market Cap
$244.74M
Gross Margin
53.14%
TTM Avg
76.57%
3Y Avg
72.53%
5Y Avg
61.83%
Market Cap
$234.93M
Gross Margin
99.39%
TTM Avg
50.00%
3Y Avg
25.00%
5Y Avg
25.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| High Tide Inc. (HITI) | $240.76M | 25.85% | 19.89% | 26.67% | 26.85% |
| Biodesix, Inc. (BDSX)vs › | $240.50M | 82.50% | 79.64% | 73.94% | 65.24% |
| InflaRx N.V. (IFRX)vs › | $241.56M | -24677.94% | -13289.35% | -6830.59% | -4553.73% |
| Galectin Therapeutics Inc. (GALT)vs › | $239.06M | 0.00% | 0.00% | 0.00% | 0.00% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $243.66M | 0.00% | 0.00% | 0.00% | 0.00% |
| Lifecore Biomedical, Inc. (LFCR)vs › | $243.81M | N/A | 31.32% | 30.59% | 32.68% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.90M | 79.48% | 71.93% | 74.52% | 72.98% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $244.74M | 53.14% | 76.57% | 72.53% | 61.83% |
| BioAge Labs Inc. (BIOA)vs › | $234.93M | 99.39% | 50.00% | 25.00% | 25.00% |
| Invivyd, Inc. (IVVD)vs › | $249.41M | 91.35% | 93.31% | 46.66% | 31.10% |
Gross Margin
25.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-07-31 | 11.38% |
| 2026-04-30 | 26.99% |
| 2026-01-31 | 8.36% |
| 2025-10-31 | 25.93% |
| 2025-07-31 | 26.78% |
| 2025-04-30 | 25.74% |
| 2025-01-31 | 24.88% |
| 2024-10-31 | 25.85% |
| 2024-07-31 | 26.92% |
| 2024-04-30 | 28.41% |
| 2024-01-31 | 28.11% |
| 2023-12-29 | 25.95% |
| 2023-07-31 | 27.81% |
| 2023-04-30 | 26.72% |
| 2023-01-31 | 27.25% |
| 2022-10-31 | 27.27% |
| 2022-07-31 | 27.01% |
| 2022-04-30 | 28.01% |
| 2022-01-31 | 31.82% |
| 2021-10-31 | 32.56% |
| 2021-07-31 | 34.70% |
| 2021-04-30 | 36.70% |
| 2021-01-31 | 38.54% |
| 2020-10-31 | 35.11% |
| 2020-07-31 | 39.58% |
| 2020-04-30 | 37.70% |
| 2020-01-31 | 34.95% |
| 2019-10-31 | 36.06% |
| 2019-07-31 | 36.92% |
| 2019-04-30 | 35.64% |
| 2019-01-31 | 35.79% |
| 2018-10-31 | -25.76% |
| 2018-07-31 | 54.11% |
| 2018-04-30 | 53.80% |
| 2018-01-31 | 53.05% |
| 2017-10-31 | 50.14% |
| 2017-07-31 | 56.51% |
